Edward Dul
Impact in
- Oncology top 5%
- Bone health and treatments
- Immunology top 10%
- Immune Response and Inflammation
Papers in
-
- Bone Metabolism and Diseases 2
- Epigenetics and DNA Methylation 1
- Protein Degradation and Inhibitors 1
- Histone Deacetylase Inhibitors Research 1
- Cell death mechanisms and regulation 1
- Oncology 2
- Peptidase Inhibition and Analysis 1
- Co-authors
- Edward R. Appelbaum (5 shared papers)Robert A. Dodds (2 shared papers)Ian E. James (2 shared papers)Martin Rosenberg (1 shared paper)Sally D. Lyn (1 shared paper)John C. Lee (1 shared paper)Keith C. Deen (1 shared paper)Carol Silverman (1 shared paper)
- Journals
- Molecular Cancer Therapeutics (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)Journal of Leukocyte Biology (1 paper)Journal of Medicinal Chemistry (1 paper)Pharmacology (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Edward Dul
8 papers receiving 1.7k citations
Edward Dul's Hit Papers
Peers
Comparison fields: 5 of 85
- Oncology 490
- Immunology 382
- Cancer Research 257
- Molecular Biology 1.3k
- Immunology and Allergy 83
Countries citing papers authored by Edward Dul
This map shows the geographic impact of Edward Dul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Dul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Dul more than expected).
Fields of papers citing papers by Edward Dul
This network shows the impact of papers produced by Edward Dul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Dul. The network helps show where Edward Dul may publish in the future.
Co-authors
The 25 scholars most cited alongside Edward Dul, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL Hit paper breakdown → | 1998 | 1030 |
| 2 | 2003 | 316 | |
| 3 | 1995 | 153 | |
| 4 | 1997 | 141 | |
| 5 | 2008 | 66 | |
| 6 | 2014 | 37 | |
| 7 | 1997 | 17 | |
| 8 | 2004 | 16 |
About Edward Dul
Edward Dul is a scholar working on Molecular Biology, Oncology, Rheumatology, Organic Chemistry and Cellular and Molecular Neuroscience, having authored 8 papers that have together received 1.8k indexed citations. Recurring topics across this work include Bone Metabolism and Diseases (2 papers), Bone and Dental Protein Studies (2 papers), Epigenetics and DNA Methylation (1 paper), NF-κB Signaling Pathways (1 paper), Protein Degradation and Inhibitors (1 paper), Histone Deacetylase Inhibitors Research (1 paper), Cell death mechanisms and regulation (1 paper) and Peptidase Inhibition and Analysis (1 paper). The work is most often cited by research in Oncology (490 citations), Immunology (382 citations), Cancer Research (257 citations), Molecular Biology (1.3k citations) and Immunology and Allergy (83 citations). Edward Dul has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Edward R. Appelbaum, Robert A. Dodds, Ian E. James, Martin Rosenberg, Sally D. Lyn, John C. Lee, Keith C. Deen, Carol Silverman, Peter R. Young and Peter McDonnell. Their work appears in journals such as Molecular Cancer Therapeutics, Journal of Pharmacology and Experimental Therapeutics, Journal of Leukocyte Biology, Journal of Medicinal Chemistry and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.